Prevention of infection in cirrhosis with Lactobacillus casei Shirota: a randomised double-blinded placebo-controlled study

niversity College London0 个研究点目标入组 92 人开始时间: 2019年4月8日最近更新: 2023年6月26日

适应症

试验速览

2020 Results article in https://doi.org/10.3390/nu12061651 (added 12/06/2023)

•1. Patients aged between 18-78 years
•2. Clinical and radiological evidence of cirrhosis, and/or biopsy proven liver cirrhosis of any cause
•3. Informed consent
•4. Abstinence from alcohol for > 2 weeks at the time of screening for inclusion

•1. Pugh score > 10
•2. Clinical evidence of active infection
•3. Antibiotic treatment within 7 days prior to enrolment
•4. Gastrointestinal haemorrhage within previous 2 weeks
•5. Use of immunomodulating agents within previous month (steroids etc)
•6. Use of proton pump inhibitors for preceding two weeks
•7. Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study
•8. Renal failure (such as hepatorenal syndrome), creatinine >150 mmol/l
•9. Hepatic encephalopathy II to IV
•10. Pancreatitis
•11. Other organ failure
•12. Hepatic or extra-hepatic malignancy
•13. Pregnancy

发起方

niversity College London